AMD

A novel formulation may prevent blood vessel growth and vascular leakage in the retina.

A team of researchers at the Ohio State University found that in mice an enzyme related to cell growth and division is a culprit in the blood vessel invasion in the back of the eye that causes blurred central vision in wet AMD.

The company announced it has received FDA approval to relaunch Susvimo for intravitreal use via an ocular implant for treating people with wet AMD.

The pharmaceutical candidate is being evaluated as a potential treat for nAMD.

The company expects approval from the EMA by 2025.

The biosimilar was approved for treating patients with age-related neovascular (wet) macular degeneration (nAMD) and other serious retinal diseases.

We asked what leaders in the retina field would tell residents and medical students as they train for the next decades in retinal care. Here's what 2 of them had to say.

According to the companies, the partnership will accelerate the development of lead product candidate, RO-104; a first-in-class tri-specific biologic for treating neovascular age-related macular degeneration.

A key distinction between patients seen in the clinic vs those enrolled in clinical trials has to do with characteristics dictated by the trial’s inclusion/exclusion criteria.

Researchers from the Case Western Reserve University School of Medicine and the Cole Eye Institute have found that supplement melatonin could be linked to a decreased risk of age-related macular degeneration.

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than the standard bimonthly aflibercept control group at all 6 time points through Week 24.

The primary endpoint for the ReNEW and ReGAIN trials is the rate of change in the macular area of photoreceptor loss assessed by spectral domain-optical coherence tomography (SD-OTC) and ellipsoid zone mapping at week 48.

The IND approval will allow the company to initiate a Phase I/IIa clinical trial for its gene therapy treatment targeting wet Age-related Macular Degeneration (AMD) including Polypoidal Choroidal Vasculopathy (PCV).

According to the company, its Phase 3 program enrolled 1,984 patients across COAST and ShORe trials. Topline data from both pivotal trials are expected in 2025.

Investigators undertook a secondary analysis of the effects of long-term, low-dose aspirin in over 3,000 older adults who satisfied the inclusion criteria in the Aspirin in Reducing Events in the Elderly–AMD (ASPREE-AMD) study.

The agency approved Yesafili (Biocon Biologics) and Opuviz (Samsung Bioepis, Biogen) as biosimilars to Eylea (Regeneron Pharmaceuticals).

The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March.

The program will use OCT images to identify and monitor AMD in its early stages.

The SAB additions include Usha Chakravarthy, MBBS, PhD; Allen Ho, MD, FACS, FASRS, and Frank Holz, MD, FEBO, FAVO.

Age-related macular degeneration continues to be a key development area for many pharmaceutical companies as the work to develop new treatment options and present data in the first few months of the year.

Research around the globe is working not only to develop treatments for AMD, but also to determine risk factors for the disease to help prevent future cases.

The European Commission is expected to make a decision about the application before the end of June.

The prevalence of AMD features in Republic of Korea Air Force pilots was higher than in other general populations studied.

David Eichenbaum, MD, FASRS discusses his clinical experience in managing retinal fluid, emphasizing the need to dramatically reduce intraretinal fluid, highlighting different strategies of care that offer the best results for patients.

Judy Kim, MD and Peter Kaiser, MD discuss the significance of fluid dynamics in nAMD and DME, highlighting the detrimental effects of fluid fluctuations and emphasize the importance of minimizing these fluctuations to achieve better visual outcomes.

David Eichenbaum, MD, FASRS discusses a case of exudative macular degeneration and opted for aflibercept 8 mg as treatment, which led to significant improvements in visual acuity and anatomical features.

After 3 loading doses, the patients were randomly assigned to receive EYP-1901 or continue to receive aflibercept at an 8-week dosing pattern for 32 weeks.

An investigation is set to launch on SpaceX’s 30th Commercial Resupply Services mission to the International Space Station contracted by NASA to test the therapy in space.